pharma · Advanced Solid Tumors
Wuhan Humanwell Innovative
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
Wuhan Humanwell Innovative is a pharma organization headquartered in CN. Primary therapeutic focus areas include Advanced Solid Tumors. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 2
- Patents
- 0
HW071021 Tablets
Phase 1 · small molecule · Advanced Solid Tumors
HW071021 Tablets for Advanced Solid Tumors is a Phase 1 program (small_molecule) at Wuhan Humanwell Innovative Drug Research and Development Center Limited Company with 1 ClinicalTrials.gov record(s).
Internal code RFSO-2024-11
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Advanced Solid Tumors
- Status
- active
- Trials
- 1